pocketful logo
Fermenta Biotech Ltd logo

Fermenta Biotech Ltd

NSE: BSE: 506414

₹336.60

(-0.80%)

Wed, 18 Mar 2026, 00:37 am

mtf coin illustrationMTF 5x

Company History

1951

  • The company was Incorporated on 1st May as a private limited company under the name International Franchise Pvt.
  • DIL was promoted by Solvay Pharmaceuticals based Brussels and Mr. D. Vasant Kumar and family in India.

1962

  • The Collaboration agreements were concluded with N.V. Philips-Duphar of Amsterdam and the Crookes Laboratories Ltd., London.

1967

  • The first phase of vitamin D manufacture was undertaken.
  • Import substitution was implemented in certain chemicals.
  • 1,200 No. of equity shares were issued at par in prop. 1:2.

1971

  • The name of the Company was changed to Duphar-Interfran Ltd.

1975

  • The second phase of vitamin D was implemented.
  • The Company's products included Crookes' transfusion, crocin and lacto-calamine.
  • 36,000 bonus shares were issued in prop. 1:1.

1977

  • 2,00,000 shares were offered to the public at a premium of Rs 2.50 per share.

1979

  • The Company undertook to set up a joint venture company under the name Fermentapharma Biodil Ltd.

1984

  • A modernisation and replacement programme was taken up at the cost of Rs 100 lakhs.
  • 4,60,000 bonus equity shares were issued in prop. 1:2.

1985

  • Profitability was affected by a strike in the Vapi unit.
  • The Company obtained registration for the manufacture of some bulk drugs and their formulations.

1988

  • The Company privately placed 1,20,000-14% non-convertible debentures of Rs 100 each for Rs 120 lakhs.
  • 4,60,000 bonus shares were issued in prop. 1:3.

1991

  • 3,22,000 shares were issued at a premium of Rs 35 per share.
  • 3,06,667 shares were issued on rights basis and 15,333 shares to employees.

1992

  • The Company continued to concentrate towards development of new formulation, bulk drugs and intermediates.
  • The Company proposed to set up a third manufacturing unit at Takwe, Maharashtra.
  • The Company introduced Vitamin D3 combination for veterinary use and Amoxycillin Dispersible Tablet.
  • The Company developed chemical preparation of Sulbactam, a beta-lactamase inhibitor.

1993

  • The Company undertook expansion programme by recreating its Vitamin D3 plant at Thane.
  • Vitamin D3 preparation in Arachis Oil for Animal Feed was developed.
  • The Company's Pilot Plant was engaged in the scaling up of in-house processes for Sulbactam and Chlorzoxazone.

1994

  • The Company proposed to issue New Equity Shares of Rs. 10/- each as Rights Shares at a premium of Rs.45 per share.
  • Two new bulk drugs namely Chlorzoxazone and Sulbactam Sodium were successfully manufactured on commercial scale.
  • Vitamin D3, liquid formulation for Animal Feed was developed and launched in the market.

1995

  • The Company offered equity shares of Rs 10 each at a premium of Rs 45 per share on rights basis to the existing shareholders.
  • The Company set up a third manufacturing unit at village Takwe (Budruk), Taluka - Maval, District - Pune.

1996

  • The Company effected sale of its main product namely, Crocin range.
  • The Company launched one of the Gynaec products under the brand name Yutopar.
  • The Company introduced Voluntary Retirement Scheme for its workmen and staff members at Thane Factory and Head Office.

1997

  • The Company launched a new product under the brand name UDILIV for chronic hepatitis, cholestasis and dissolution of gall stones indications.
  • The Company has an R & D Laboratory approved by DSIR for chemicals and pharmaceutical research and development activity.
  • A wage settlement was signed with Unions of Medical Representatives and a wage agreement with the Union of Thane and H.O. Workmen and Staff.

1998

  • Duphar-Interfran is present in categories like antibiotics, anti-stress therapy, iodine therapy and muscle spasm.
  • The company launched a product under the brand name Udiliv for chronic hepatitis, cholestasis and dissolution of gall stones indications.

1999

  • The Company continued research programme for finding out new lead molecules of medicinal importance and development of indigenous technologies for major drugs and intermediates.
  • The Company installed electrical capacitors to maintain power factor at an efficient level.
  • The Company has an extensive computer network.

2000

  • Duphar-Interfran Ltd said it is demerging its pharmaceutical business into a new company.
  • The Company signed agreements with NSDL and CDSL for dematerialisation of the company's shares and for electronic connectivity.

2002

  • Mr Kunal Kashyap was appointed as a Director on the Board of the company.

2005

  • The Registered Office of the Company was shifted from Worli, Mumbai to Thane.

2007

  • Dil Ltd appointed Mr. Sanjay Buch as an additional director (Independent Category).

2008

  • Dil Ltd recommended an equity dividend of 100%.

2009

  • Dil Ltd declared Interim Dividend and recommended Final Dividend of Rs 7.50 per share.

2010

  • Dil Ltd declared Interim Dividend at Rs. 7.50/- per equity share.
  • Dil Ltd recommended final equity dividend at Rs. 7.50/- per equity share.

2011

  • Dil Ltd declared interim equity dividend at Rs. 15/- per equity share.
  • Dil Ltd recommended final equity dividend at Rs. 10/- per equity share.

2012

  • Dil Ltd declared interim equity dividend at Rs. 15/- per equity share.
  • Dil Ltd recommended final equity dividend at Rs. 15/- per equity share.

2013

  • Dil Ltd signed an Agreement with Advertising Agents and Consultants.

2014

  • The Board appointed Dr. Gopakumar Nair as an Additional Director of the company.

2016

  • Dil Ltd shifted its registered office to A -1601, Thane One, DIL Complex, Ghodbunder Road, Majiwade, Thane (West) 400 610, Maharashtra, India.

2018

  • The Company issued Bonus Shares in the Ratio of 1:1.

2019

  • The company name was changed to Fermenta Biotech Ltd. from DIL Ltd.

2020

  • The Company issued Bonus Shares in the Ratio of 2:1.

2021

  • Fermenta received the Pride of Maharashtra Awards 2021 as the Best Company of the Year for Excellence in Exports.
  • Fermenta was awarded as the runner up in the category Excellence in R&D for the Development of new Product/ technology in India Pharma Awards 2021.

2023

  • Fermenta received the Excellence in Logistics Performance - Pharma Award at the 5th India Logistics and Warehousing Excellence Awards 2023.

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Stocks:

AllABCDEFGHIJKLMNOPQRSTUVWXYZ

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Others:

NSEBSECDSLNSDLSEBIMCXMSEINCDEXNSE IFSCINDIA INXAccount Closure FormDP Investor CharterBroker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800